Davies FE - Search Results

1

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma.

Ashby C, Boyle EM, Bauer MA, Mikulasova A, Wardell CP, Williams L, Siegel A, Blaney P, Braunstein M, Kaminetsky D, Keats J, Maura F, Landgren O, Walker BA, Davies FE, Morgan GJ. Ashby C, et al. Among authors: davies fe. Blood Cancer J. 2022 May 30;12(5):85. doi: 10.1038/s41408-022-00673-x. Blood Cancer J. 2022. PMID: 35637217 Free PMC article.

2

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1997 Apr;97(1):46-55. doi: 10.1046/j.1365-2141.1997.72653.x. Br J Haematol. 1997. PMID: 9136941 Free article.

3

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

4

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

5

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

6

True spectrum of 14q32 translocations in multiple myeloma.

Pratt G, Fenton JA, Proffitt JA, Rawstron AC, Davies FE, Child JA, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 1998 Dec;103(4):1209-10. doi: 10.1046/j.1365-2141.1998.1161d.x. Br J Haematol. 1998. PMID: 9886346 Free article. No abstract available.

7

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. Davies FE, et al. J Clin Oncol. 2000 Aug;18(15):2843-51. doi: 10.1200/JCO.2000.18.15.2843. J Clin Oncol. 2000. PMID: 10920132

8

Controversies surrounding the clonogenic origin of multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Br J Haematol. 2000 Jul;110(1):240-1. doi: 10.1046/j.1365-2141.2000.02072-6.x. Br J Haematol. 2000. PMID: 10931011 Free article. No abstract available.

9

Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma.

Dring AM, Davies FE, Rollinson SJ, Roddam PL, Rawstron AC, Child JA, Jack AS, Morgan GJ. Dring AM, et al. Among authors: davies fe. Br J Haematol. 2001 Jan;112(1):249-51. doi: 10.1046/j.1365-2141.2001.02497-2a.x. Br J Haematol. 2001. PMID: 11167813 Free article. No abstract available.

10

Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma.

Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 2001 Feb;112(2):388-91. doi: 10.1046/j.1365-2141.2001.02588.x. Br J Haematol. 2001. PMID: 11167836 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters